The Immunological Monitoring Core provides immunologic and biological assay support for ongoing research projects and clinical trials at the Cancer Center and the biomedical community at the University of Michigan. Services are provided in three different areas. First, simultaneous detection of numerous cytokines, chemokines, hormones and other released proteins and the related technical support are provided on a continued basis for investigators. These assays are performed with the Luminex System, and via ELISA using a robotics pipetting station. Second, TAA-specific T cell response assays will be provided to investigators. These assays Include TAA-specific cytokine ELISA spot by using the AID ELISPOT Plate Reader, and TAA-specific T cell proliferation and CTL activities. Third, the Core provides time standard technical services to support clinical research protocols in the immunobiology area for Investigators who do not have standard wet laboratory space. This facility will provide the opportunity to have tissues processed and analyzed for general immune parameters, standard lymphocyte and tumor proliferation assays, as well as quantification of cytokines. These Immune assays may not nomially be available In the non-immunology laboratory, The Core also provides expert advice that helps investigators select appropriate immune assays using appropriate reagents and apply them to best advantage.
The services provided by the immune Monitoring Core support research by investigators involved in immunological approaches to the treatment of cancer. The overall goal of this core is to extend or improve the quality of life of cancer patients through immune mechanisms.
|Lee, Alice W; Ness, Roberta B; Roman, Lynda D et al. (2016) Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. Obstet Gynecol 127:828-36|
|Mathewson, Nathan D; Jenq, Robert; Mathew, Anna V et al. (2016) Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat Immunol 17:505-13|
|Owen, John Henry; Graham, Martin P; Chinn, Steven B et al. (2016) Novel method of cell line establishment utilizing fluorescence-activated cell sorting resulting in 6 new head and neck squamous cell carcinoma lines. Head Neck 38 Suppl 1:E459-67|
|Peng, Dongjun; Tanikawa, Takashi; Li, Wei et al. (2016) Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling. Cancer Res 76:3156-65|
|Kadakia, Kunal C; Snyder, Claire F; Kidwell, Kelley M et al. (2016) Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer. Oncologist 21:539-46|
|Boonstra, Philip S; Mukherjee, Bhramar; Gruber, Stephen B et al. (2016) Tests for Gene-Environment Interactions and Joint Effects With Exposure Misclassification. Am J Epidemiol 183:237-47|
|Amin, Nisar A; Malek, Sami N (2016) Gene mutations in chronic lymphocytic leukemia. Semin Oncol 43:215-21|
|Hardiman, Karin M; Ulintz, Peter J; Kuick, Rork D et al. (2016) Intra-tumor genetic heterogeneity in rectal cancer. Lab Invest 96:4-15|
|Boonstra, Philip S; Taylor, Jeremy M G; Smolska-Ciszewska, Beata et al. (2016) Alpha/beta (Î±/Î²) ratio for prostate cancer derived from external beam radiotherapy and brachytherapy boost. Br J Radiol 89:20150957|
|Di Girolamo, Daniela; Ambrosio, Raffaele; De Stefano, Maria A et al. (2016) Reciprocal interplay between thyroid hormone and microRNA-21 regulates hedgehog pathway-driven skin tumorigenesis. J Clin Invest 126:2308-20|
Showing the most recent 10 out of 1165 publications